{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:43:00Z","timestamp":1790185380720,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["HHSA 290-2017-00003C"],"award-info":[{"award-number":["HHSA 290-2017-00003C"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.mayocp.2024.03.023","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:53:16Z","timestamp":1724979196000},"page":"1722-1731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Safety of Triptans in Patients Who Have or Are at High Risk for Cardiovascular Disease"],"prefix":"10.1016","volume":"99","author":[{"given":"Zhen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana H.","family":"VanderPluym","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi B.","family":"Halker Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem A.","family":"Alsibai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Roellinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Firwana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5502-5975","authenticated-orcid":false,"given":"Mohammad Hassan","family":"Murad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.mayocp.2024.03.023_bib1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","article-title":"Migraine: epidemiology, burden, and comorbidity","volume":"37","author":"Burch","year":"2019","journal-title":"Neurol Clin"},{"key":"10.1016\/j.mayocp.2024.03.023_bib2","series-title":"Acute Treatments for Episodic Migraine. Comparative Effectiveness Reviews, No. 239","author":"Singh","year":"2020"},{"issue":"23","key":"10.1016\/j.mayocp.2024.03.023_bib3","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1001\/jama.2021.7939","article-title":"Acute treatments for episodic migraine in adults: a systematic review and meta-analysis","volume":"325","author":"VanderPluym","year":"2021","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.mayocp.2024.03.023_bib4","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/head.13179","article-title":"Framingham-based cardiovascular risk estimates among people with episodic migraine in the US population: results from the American Migraine Prevalence and Prevention (AMPP) study","volume":"57","author":"Lipton","year":"2017","journal-title":"Headache"},{"issue":"1","key":"10.1016\/j.mayocp.2024.03.023_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/head.12962","article-title":"Cardiovascular events, conditions, and procedures among people with episodic migraine in the US population: results from the American Migraine Prevalence and Prevention (AMPP) study","volume":"57","author":"Buse","year":"2017","journal-title":"Headache"},{"issue":"7","key":"10.1016\/j.mayocp.2024.03.023_bib6","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/head.12870","article-title":"How to apply the AHS evidence assessment of the acute treatment of migraine in adults to your patient with migraine","volume":"56","author":"Pringsheim","year":"2016","journal-title":"Headache"},{"key":"10.1016\/j.mayocp.2024.03.023_bib7","article-title":"Triptans use for migraine headache among nonelderly adults with cardiovascular risk","volume":"2016","author":"Alwhaibi","year":"2016","journal-title":"Pain Res Treat"},{"issue":"1","key":"10.1016\/j.mayocp.2024.03.023_bib8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40120-021-00304-w","article-title":"Epidemiology, demographics, triptan contraindications, and prescription patterns of patients with migraine: a German claims database study","volume":"11","author":"Gendolla","year":"2022","journal-title":"Neurol Ther"},{"issue":"7","key":"10.1016\/j.mayocp.2024.03.023_bib9","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/head.14327","article-title":"Triptan medication use among patients with migraine with contraindications in the US","volume":"62","author":"Pero","year":"2022","journal-title":"Headache"},{"issue":"6","key":"10.1016\/j.mayocp.2024.03.023_bib10","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1007\/s11606-020-05783-5","article-title":"A\u00a0narrative review and proposed framework for using health system data with systematic reviews to support decision-making","volume":"35","author":"Lin","year":"2020","journal-title":"J\u00a0Gen Intern Med"},{"issue":"9","key":"10.1016\/j.mayocp.2024.03.023_bib11","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/aje\/kwq224","article-title":"Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score","volume":"172","author":"Austin","year":"2010","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.mayocp.2024.03.023_bib12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/00031305.1985.10479383","article-title":"Constructing a control group using multivariate matched sampling methods that incorporate the propensity score","volume":"39","author":"Rosenbaum","year":"1985","journal-title":"The American Statistician"},{"issue":"suppl 8","key":"10.1016\/j.mayocp.2024.03.023_bib13","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jclinepi.2013.01.013","article-title":"Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research","volume":"66","author":"Stuart","year":"2013","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.mayocp.2024.03.023_bib14","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1037\/a0019623","article-title":"Propensity score techniques and the assessment of measured covariate balance to test causal associations in psychological research","volume":"15","author":"Harder","year":"2010","journal-title":"Psychol Methods"},{"key":"10.1016\/j.mayocp.2024.03.023_bib15","series-title":"Econometric Analysis of Cross Section and Panel Data","author":"Wooldridge","year":"2010"},{"issue":"3","key":"10.1016\/j.mayocp.2024.03.023_bib16","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1468-2982.2008.01726.x","article-title":"Treatment choices and patterns in migraine patients with and without a cardiovascular risk profile","volume":"29","author":"Wammes-van der Heijden","year":"2009","journal-title":"Cephalalgia"},{"issue":"2","key":"10.1016\/j.mayocp.2024.03.023_bib17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s40122-020-00167-3","article-title":"Acute migraine prescription patterns vary by baseline cardiovascular risk and clinical characteristics: a real-world evidence study","volume":"9","author":"Li","year":"2020","journal-title":"Pain Ther"},{"issue":"2","key":"10.1016\/j.mayocp.2024.03.023_bib18","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1526-4610.2009.01595.x","article-title":"Triptan use as a function of cardiovascular risk. A population-based study","volume":"50","author":"Bigal","year":"2010","journal-title":"Headache"},{"issue":"7","key":"10.1016\/j.mayocp.2024.03.023_bib19","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1526-4610.2000.00091.x","article-title":"Cardiac risk factors and the use of triptans: a survey study","volume":"40","author":"Young","year":"2000","journal-title":"Headache"},{"issue":"5","key":"10.1016\/j.mayocp.2024.03.023_bib20","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/head.14304","article-title":"Triptans and vascular comorbidity in persons over fifty: findings from a nationwide insurance database \u2014 a cohort study","volume":"62","author":"Zebenholzer","year":"2022","journal-title":"Headache"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2024.03.023_bib21","first-page":"S20","article-title":"Cardiovascular tolerability and safety of triptans: a review of clinical data","volume":"44","author":"Dodick","year":"2004","journal-title":"Headache"},{"issue":"5","key":"10.1016\/j.mayocp.2024.03.023_bib22","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1526-4610.2004.04078.x","article-title":"Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine","volume":"44","author":"Dodick","year":"2004","journal-title":"Headache"},{"issue":"10","key":"10.1016\/j.mayocp.2024.03.023_bib23","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1111\/head.13959","article-title":"Risk of acute myocardial infarction, heart failure, and death in migraine patients treated with triptans","volume":"60","author":"Ghanshani","year":"2020","journal-title":"Headache"},{"issue":"4","key":"10.1016\/j.mayocp.2024.03.023_bib24","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1212\/01.WNL.0000110312.36809.7F","article-title":"Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice","volume":"62","author":"Hall","year":"2004","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.mayocp.2024.03.023_bib25","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s10194-021-01338-z","article-title":"Risk for ischemic stroke and coronary heart disease associated with migraine and migraine medication among older adults","volume":"22","author":"McKinley","year":"2021","journal-title":"J\u00a0Headache Pain"},{"issue":"2","key":"10.1016\/j.mayocp.2024.03.023_bib26","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/0333102414550416","article-title":"Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies","volume":"35","author":"Roberto","year":"2015","journal-title":"Cephalalgia"},{"issue":"3","key":"10.1016\/j.mayocp.2024.03.023_bib27","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/jamaneurol.2023.5549","article-title":"Risk of stroke and myocardial infarction among initiators of triptans","volume":"81","author":"Petersen","year":"2024","journal-title":"JAMA Neurol"},{"issue":"10","key":"10.1016\/j.mayocp.2024.03.023_bib28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.28544","article-title":"Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis","volume":"4","author":"Yang","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.mayocp.2024.03.023_bib29","doi-asserted-by":"crossref","DOI":"10.1177\/03331024221143773","article-title":"Place of next generation acute migraine specific treatments among triptans, non-responders and contraindications to triptans and possible combination therapies","volume":"43","author":"de Boer","year":"2023","journal-title":"Cephalalgia"},{"issue":"24","key":"10.1016\/j.mayocp.2024.03.023_bib30","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data","volume":"328","author":"Hernan","year":"2022","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.mayocp.2024.03.023_bib31","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1111\/head.12150","article-title":"Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American Migraine Prevalence and Prevention (AMPP) study","volume":"53","author":"Buse","year":"2013","journal-title":"Headache"},{"issue":"5","key":"10.1016\/j.mayocp.2024.03.023_bib32","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1468-2982.2009.01941.x","article-title":"Global prevalence of chronic migraine: a systematic review","volume":"30","author":"Natoli","year":"2010","journal-title":"Cephalalgia"},{"issue":"9","key":"10.1016\/j.mayocp.2024.03.023_bib33","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/j.1526-4610.2006.00577.x","article-title":"Modifiable risk factors for migraine progression","volume":"46","author":"Bigal","year":"2006","journal-title":"Headache"},{"issue":"12","key":"10.1016\/j.mayocp.2024.03.023_bib34","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/clc.22219","article-title":"Mediators of Atherosclerosis in South Asians Living in America (MASALA) study: objectives, methods, and cohort description","volume":"36","author":"Kanaya","year":"2013","journal-title":"Clin Cardiol"},{"issue":"2","key":"10.1016\/j.mayocp.2024.03.023_bib35","article-title":"Association of American identity with cardiovascular health in South Asian Americans: the MASALA study","volume":"3","author":"Sunderraj","year":"2023","journal-title":"J\u00a0Asian Health"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619624001642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619624001642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:06:54Z","timestamp":1777388814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619624001642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0025619624001642"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2024.03.023","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of Triptans in Patients Who Have or Are at High Risk for Cardiovascular Disease","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2024.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}